drugset / Trial / NCT01214629
A Study for Participants With Advanced Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is being conducted to determine the safety of LY2523355 for the treatment of advanced and/or metastatic cancer (including Non-Hodgkin's lymphoma).
Timeline
- Start
- 2007-07
- Primary completion
- 2012-05
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | litronesib | Small molecule | 0.125 mg/m2 | Intravenous |
| Subject | litronesib | Small molecule | 4 mg/m2 | Intravenous |
| Background | Pegfilgrastim | Protein / enzyme biologic | 6 mg | Subcutaneous |